0.36
0.36 (0%)
As of Apr 17, 2025
Leap Therapeutics, Inc. [LPTX]
Source:
Company Overview
Leap Therapeutics, Inc. is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | 617 252 4343 |
| Industry | manufacturing |
| CEO | Douglas E. Onsi |
| Website | www.leaptx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-70.1 |
| Net Income | $-67.6 |
| Net Cash | $-23.4 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -110.8% |
| Profit as % of Stockholder Equity | -192.8% |
Management Effectiveness
| Return on Equity | -192.8% |
| Return on Assets | -137.5% |
| Turnover Ratio | |
| EBITA | $-70.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $49.1 |
| Total Liabilities | $14.1 |
| Operating Cash Flow | $-60.3 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $37.2 |
